KR20230163185A - Composition for the prevention or treatment of obesity comprising an immature fruit extract of Cornus officinalis as an active ingredient - Google Patents
Composition for the prevention or treatment of obesity comprising an immature fruit extract of Cornus officinalis as an active ingredient Download PDFInfo
- Publication number
- KR20230163185A KR20230163185A KR1020220062967A KR20220062967A KR20230163185A KR 20230163185 A KR20230163185 A KR 20230163185A KR 1020220062967 A KR1020220062967 A KR 1020220062967A KR 20220062967 A KR20220062967 A KR 20220062967A KR 20230163185 A KR20230163185 A KR 20230163185A
- Authority
- KR
- South Korea
- Prior art keywords
- cornus officinalis
- extract
- clause
- present
- cornus
- Prior art date
Links
- 241000759833 Cornus officinalis Species 0.000 title claims abstract description 183
- 239000000284 extract Substances 0.000 title claims abstract description 149
- 239000000203 mixture Substances 0.000 title claims abstract description 32
- 235000013399 edible fruits Nutrition 0.000 title claims abstract description 30
- 239000004480 active ingredient Substances 0.000 title claims abstract description 28
- 208000008589 Obesity Diseases 0.000 title claims abstract description 26
- 235000020824 obesity Nutrition 0.000 title claims abstract description 26
- 238000011282 treatment Methods 0.000 title description 10
- 230000002265 prevention Effects 0.000 title description 3
- 238000009825 accumulation Methods 0.000 claims abstract description 60
- YTZSBJLNMIQROD-SFBCHFHNSA-N Morroniside Chemical compound O([C@@H]1OC=C([C@H]2C[C@H](O)O[C@@H](C)[C@H]21)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YTZSBJLNMIQROD-SFBCHFHNSA-N 0.000 claims abstract description 26
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims abstract description 26
- HLXRWTJXGMHOFN-XJSNKYLASA-N Verbenalin Chemical compound O([C@@H]1OC=C([C@H]2C(=O)C[C@H](C)[C@H]21)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HLXRWTJXGMHOFN-XJSNKYLASA-N 0.000 claims abstract description 22
- 230000001965 increasing effect Effects 0.000 claims abstract description 18
- UGWAFWFSLCHCJD-UHFFFAOYSA-N Cornuside Natural products OC1C(O)C(O)C(CO)OC1OC1C(C=C)C(CCOC(=O)C=2C=C(O)C(O)=C(O)C=2)C(C(O)=O)=CO1 UGWAFWFSLCHCJD-UHFFFAOYSA-N 0.000 claims abstract description 14
- SMTKSCGLXONVGL-ZEIULZLQSA-N methyl (2r,3s,4r)-3-ethenyl-4-[2-(3,4,5-trihydroxybenzoyl)oxyethyl]-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4-dihydro-2h-pyran-5-carboxylate Chemical compound O([C@H]1OC=C([C@@H]([C@@H]1C=C)CCOC(=O)C=1C=C(O)C(O)=C(O)C=1)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SMTKSCGLXONVGL-ZEIULZLQSA-N 0.000 claims abstract description 14
- YTZSBJLNMIQROD-UHFFFAOYSA-N (4aS)-1c-beta-D-glucopyranosyloxy-6xi-hydroxy-8t-methyl-(4ar,8ac)-5,6,8,8a-tetrahydro-1H,4aH-pyrano[3,4-c]pyran-4-carboxylic acid methyl ester Natural products C12C(C)OC(O)CC2C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O YTZSBJLNMIQROD-UHFFFAOYSA-N 0.000 claims abstract description 13
- AMBQHHVBBHTQBF-UHFFFAOYSA-N Loganin Natural products C12C(C)C(O)CC2C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O AMBQHHVBBHTQBF-UHFFFAOYSA-N 0.000 claims abstract description 13
- VSJGJMKGNMDJCI-ZASXJUAOSA-N Sweroside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](C=C)[C@H](CCOC2=O)C2=CO1 VSJGJMKGNMDJCI-ZASXJUAOSA-N 0.000 claims abstract description 13
- 235000004515 gallic acid Nutrition 0.000 claims abstract description 13
- 229940074391 gallic acid Drugs 0.000 claims abstract description 13
- AMBQHHVBBHTQBF-UOUCRYGSSA-N loganin Chemical compound O([C@@H]1OC=C([C@H]2C[C@H](O)[C@H](C)[C@H]21)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O AMBQHHVBBHTQBF-UOUCRYGSSA-N 0.000 claims abstract description 13
- VSJGJMKGNMDJCI-QXSNVGMTSA-N sweroside Natural products OC[C@H]1O[C@H](O[C@@H]2OC=C3[C@@H](CCOC3=O)[C@H]2C=C)[C@H](O)[C@@H](O)[C@@H]1O VSJGJMKGNMDJCI-QXSNVGMTSA-N 0.000 claims abstract description 13
- HLXRWTJXGMHOFN-UHFFFAOYSA-N Verbenalin Natural products C12C(C)CC(=O)C2C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O HLXRWTJXGMHOFN-UHFFFAOYSA-N 0.000 claims abstract description 11
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 11
- 235000013305 food Nutrition 0.000 claims description 26
- 239000002904 solvent Substances 0.000 claims description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 102100034808 CCAAT/enhancer-binding protein alpha Human genes 0.000 claims description 10
- 239000004615 ingredient Substances 0.000 claims description 10
- 101710168309 CCAAT/enhancer-binding protein alpha Proteins 0.000 claims description 9
- 108010016731 PPAR gamma Proteins 0.000 claims description 9
- 102100034798 CCAAT/enhancer-binding protein beta Human genes 0.000 claims description 7
- 101710134031 CCAAT/enhancer-binding protein beta Proteins 0.000 claims description 7
- 238000005406 washing Methods 0.000 claims description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 238000003786 synthesis reaction Methods 0.000 claims description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 102000000536 PPAR gamma Human genes 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 23
- 108090000623 proteins and genes Proteins 0.000 abstract description 12
- 102000004169 proteins and genes Human genes 0.000 abstract description 11
- 210000001789 adipocyte Anatomy 0.000 description 35
- 238000003306 harvesting Methods 0.000 description 30
- 230000004069 differentiation Effects 0.000 description 28
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 16
- 238000010586 diagram Methods 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 10
- 231100000135 cytotoxicity Toxicity 0.000 description 10
- 230000003013 cytotoxicity Effects 0.000 description 10
- 235000013376 functional food Nutrition 0.000 description 10
- 239000000546 pharmaceutical excipient Substances 0.000 description 10
- 230000003579 anti-obesity Effects 0.000 description 9
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 9
- 229960003957 dexamethasone Drugs 0.000 description 9
- 239000000796 flavoring agent Substances 0.000 description 9
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 8
- 102000004877 Insulin Human genes 0.000 description 8
- 108090001061 Insulin Proteins 0.000 description 8
- 235000013355 food flavoring agent Nutrition 0.000 description 8
- 230000036541 health Effects 0.000 description 8
- 229940125396 insulin Drugs 0.000 description 8
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 7
- 238000012790 confirmation Methods 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 240000006766 Cornus mas Species 0.000 description 4
- 235000003363 Cornus mas Nutrition 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000007884 disintegrant Substances 0.000 description 4
- 235000013373 food additive Nutrition 0.000 description 4
- 239000002778 food additive Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 208000001145 Metabolic Syndrome Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000012752 auxiliary agent Substances 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- -1 pH adjusters Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 102100039164 Acetyl-CoA carboxylase 1 Human genes 0.000 description 2
- 101710159293 Acyl-CoA desaturase 1 Proteins 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 102000015303 Fatty Acid Synthases Human genes 0.000 description 2
- 108010039731 Fatty Acid Synthases Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101000963424 Homo sapiens Acetyl-CoA carboxylase 1 Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 231100000002 MTT assay Toxicity 0.000 description 2
- 238000000134 MTT assay Methods 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 102000004311 liver X receptors Human genes 0.000 description 2
- 108090000865 liver X receptors Proteins 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- SLYRGJDSFOCAAI-UHFFFAOYSA-N 1,3-thiazolidin-2-one Chemical compound O=C1NCCS1 SLYRGJDSFOCAAI-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 108010065459 CCAAT-Enhancer-Binding Protein-alpha Proteins 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 241000142975 Cornaceae Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 244000147568 Laurus nobilis Species 0.000 description 1
- 235000017858 Laurus nobilis Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 108010074436 Sterol Regulatory Element Binding Protein 1 Proteins 0.000 description 1
- 102100026839 Sterol regulatory element-binding protein 1 Human genes 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 235000005212 Terminalia tomentosa Nutrition 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000011759 adipose tissue development Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000000748 compression moulding Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000019439 energy homeostasis Effects 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229940050549 fiber Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 229940125722 laxative agent Drugs 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 235000019462 natural additive Nutrition 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 230000031787 nutrient reservoir activity Effects 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000003614 peroxisome proliferator Substances 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/40—Cornaceae (Dogwood family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Child & Adolescent Psychology (AREA)
- Medical Informatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
산수유 미성숙과 추출물을 유효성분으로 포함하는 비만 예방 또는 치료용 조성물에 관한 것으로서, 본 발명은, 산수유 미성숙과 추출물이, 지방축적 억제 효과가 우수한 것을 확인하였으며, 지방 축적과 관련된 단백질의 발현을 억제시키는 것을 확인하였다. 또한, 산수유 미성숙과 추출물 중 씨앗을 포함한 추출물이, 과육 추출물보다 지방축적 및 지방 축적 단백질의 발현을 억제시키는 효과가 우수한 것을 확인하였으며, 산수유 미성숙과 추출물에서, 갈릭산(gallic acid), 모로니사이드(Morroniside), 로가닌(Loganin), 베르베날린(Verbenalin), 스와로사이드(Sweroside) 및 콘누사이드(Cornuside)의 함량이 증가된 것을 확인하였다.The present invention relates to a composition for preventing or treating obesity containing an extract of immature Cornus officinalis as an active ingredient. The present invention confirms that the immature Cornus officinalis fruit extract is excellent in the effect of inhibiting fat accumulation, and inhibits the expression of proteins related to fat accumulation. confirmed. In addition, it was confirmed that among the extracts of immature Cornus officinalis fruit, extracts containing seeds were more effective than pulp extracts in suppressing fat accumulation and the expression of fat accumulation proteins. In the extracts of immature Cornus officinalis fruit, gallic acid and moroniside were found. It was confirmed that the contents of Morroniside, Loganin, Verbenalin, Sweroside, and Cornuside were increased.
Description
본 발명은, 산수유 미성숙과 추출물을 유효성분으로 포함하는 비만 예방 또는 치료용 조성물에 관한 것이다.The present invention relates to a composition for preventing or treating obesity comprising an extract of immature Cornus officinalis as an active ingredient.
비만은 음식물의 섭취와 에너지의 사용의 불균형으로 초래되는 질병으로, 암, 제2형 당뇨병 및 동맥경화증 등 심각한 질병을 동반할 수 있다. 최근에는 비만, 당뇨, 동맥경화, 고지혈증, 고혈압 등을 대사증후군으로 부르고 있으며, 이에 대한 관심이 증가하여 세계 각국에서 연구가 진행되고 있다. 비만의 원인을 이해하고 이에 대응하고자 하는 전세계적인 노력에도 불구하고, 비만은 가속적으로 증가하고 있다. WTO는 "비만은 장기적인 투명이 필요한 질병이다"라고 경고하고 있는 가운데, 비만은 단순히 미관상의 문제로 그칠 문제가 아니라 각종 질병을 유발하여 생명을 위협하는 심각한 질환이라는 인식이 확대되고 있다.Obesity is a disease caused by an imbalance between food intake and energy use, and can be accompanied by serious diseases such as cancer, type 2 diabetes, and arteriosclerosis. Recently, obesity, diabetes, arteriosclerosis, hyperlipidemia, and high blood pressure have been called metabolic syndrome, and interest in this is increasing, with research being conducted around the world. Despite global efforts to understand and respond to the causes of obesity, obesity is increasing at an accelerated rate. While the WTO warns that "Obesity is a disease that requires long-term transparency," awareness is growing that obesity is not just a cosmetic problem, but a serious disease that causes various diseases and threatens life.
비만의 발생은 유전적, 사회적 및 경제적 요인 등의 복잡한 요인과 함께 운동량의 사회적 감소와 고열량 음식의 섭취량 증가로 인한 에너지 항상성 조절 실패가 원인으로 보고되고 있다. 최근에는 고칼로리 음식의 섭취와 육체 활동 저하에 의해 발병하는 것으로 알려진 2형 당뇨병을 포함하는 대사증후군과 연관된 비만의 발병이 세계적으로 증가하고 있다. 또한, 2025년에는 이러한 대사증후군을 가진 인구가 2배로 늘어나 약 3억 명에 이를 것으로 예측되고 있다. 비만은 인체의 에너지 섭취와 소모의 불균형의 결과로써, 지방축적에 의하여 지방세포의 크기가 증가하고 섬유아세포가 지방세포로 분화함으로써 지방세포의 수가 증가한 결과이다. 섬유아세포가 분화하여 지방세포로 생성되는 과정(adipogenesis)에는 CCAAT enhancer-binding protein-α (C/EBPα), peroxisome proliferators-activated receptor-γ (PPARγ), liver X receptor α (LXRα), sterol regulatory element binding protein-1c (SREBP-1c)와 같은 다양한 전사인자들이 관여한다. 이러한 전사인자들은 지방조직에서 많이 발현되고 지방세포로의 분화시에 그들의 활성화는 fatty acid synthase (FAS), stearoyl-CoA desaturase-1 (SCD-1), acetyl-CoA carboxylase-α (ACCα)와 같은 지방합성유전자들의 발현을 직접적으로 향상시켜 분화된 지방세포에 지방축적을 증가시킨다. 이러한 이유 때문에 항비만제를 개발하기 위하여 지방세포분화나 지방합성에 관여하는 전사인자나 유전자들의 활성을 억제시키는 천연물질을 찾기 위한 많은 연구가 진행되고 있다.The occurrence of obesity is reported to be caused by complex factors such as genetic, social, and economic factors, as well as failure to control energy homeostasis due to a social decrease in the amount of exercise and an increase in the intake of high-calorie foods. Recently, the incidence of obesity associated with metabolic syndrome, including type 2 diabetes, which is known to be caused by consumption of high-calorie foods and reduced physical activity, is increasing worldwide. In addition, it is predicted that the population with metabolic syndrome will double by 2025, reaching approximately 300 million. Obesity is the result of an imbalance between the body's energy intake and consumption, and the size of fat cells increases due to fat accumulation and the number of fat cells increases as fibroblasts differentiate into adipocytes. The process by which fibroblasts differentiate into adipocytes (adipogenesis) involves CCAAT enhancer-binding protein-α (C/EBPα), peroxisome proliferators-activated receptor-γ (PPARγ), liver X receptor α (LXRα), and sterol regulatory element. Various transcription factors such as binding protein-1c (SREBP-1c) are involved. These transcription factors are expressed in large quantities in adipose tissue, and their activation during differentiation into adipocytes involves fatty acid synthase (FAS), stearoyl-CoA desaturase-1 (SCD-1), and acetyl-CoA carboxylase-α (ACCα). It directly improves the expression of synthetic genes and increases fat accumulation in differentiated adipocytes. For this reason, in order to develop anti-obesity drugs, much research is being conducted to find natural substances that inhibit the activity of transcription factors or genes involved in adipocyte differentiation or fat synthesis.
현재 비만을 치료하기 위한 다양한 방법이 시도되고 있다. 일반적으로 비만증의 치료법은 식이요법, 운동요법, 식욕 억제제, 이뇨제, 설사제 또는 포만감을 주기 위한 섬유질 등을 사용하는 약물요법, 잘못된 식습관과 생활 습관을 교정해 주는 행동수정요법, 외과에서 장이나 위의 용적을 줄이는 수술요법, 성형외과 등에서 초음파를 이용하여 지방세포를 분해, 제거하는 방법 등의 지방제거수술 등이 있다. 또한, 비만 치료와 관련된 암페타민, 리덕틸, 티아졸리디네온, 메트포르민 등은 다양한 부작용이 나타나고 있으며, 이러한 이유로 최근에는 비만 치료와 관련하여 약용 식물의 사용을 포함한 대체 접근법에 대한 관심이 증대되고 있으며, 체내에 대해 안정성이 인정된 천연물로부터 새로운 비만 예방 및 개선 치료제의 개발이 필요한 실정이다.Currently, various methods are being tried to treat obesity. In general, treatments for obesity include diet, exercise therapy, drug therapy using appetite suppressants, diuretics, laxatives, or fiber to provide a feeling of fullness, behavior modification therapy to correct incorrect eating habits and lifestyle habits, and surgery to treat the intestines or stomach. There are surgical treatments to reduce the volume of the body and fat removal surgeries, such as methods in plastic surgery that use ultrasound to break down and remove fat cells. In addition, amphetamines, reductyl, thiazolidineone, metformin, etc. related to the treatment of obesity have various side effects, and for this reason, interest in alternative approaches, including the use of medicinal plants, has recently increased in relation to the treatment of obesity. There is a need to develop new obesity prevention and improvement treatments from natural products whose safety has been recognized.
한편, 산수유(Cornus officinalis)는 층층나무과(Comaceae)에 속하는 약용식물로 그 열매는 길이 1.5cm 내외의 중추원형의 모양이며, 신맛이 두드러져 촉산초라고도 불리며, 자양강장 효과를 가진 천연식품으로 널리 이용되고 있다. 산수유는 대표적인 약용열매로 국내에서 활발히 사용하고 있으며, 산수유의 일반적인 수확시기는 11월로 10월부터 붉은 색으로 발색이 되고, 11월에 잎이 떨어지고 수분이 감소하고 말랑해지면 수확하여 씨를 제거하고 건조하여 시중에 유통되고 있다. 수확시기에 따른 기능성 연구는 많이 이루어지고 있으며, 산수유 또한 기능성, 기능성분에 대한 수확시기별 연구가 이루어졌으나, 미숙과에 대하여는 연구가 미비한 실정이다. 또한, 산수유는 유통과정 전, 씨를 제거하여 유통되기에, 산수유 씨앗은 농가폐기물로 단순히 버려지고 있는 실정이다. Meanwhile, Cornus officinalis is a medicinal plant belonging to the dogwood family (Comaceae). Its fruit is about 1.5 cm long and has a central circular shape. It is also called Chosancho due to its pronounced sour taste. It is widely used as a natural food with a nourishing and tonic effect. It is becoming. Cornus officinalis is a representative medicinal fruit and is actively used in Korea. The general harvest time for Cornus officinalis is November. It starts to turn red in October, and in November, when the leaves fall and moisture decreases and becomes soft, it is harvested, the seeds are removed, and the fruit is dried. It is being distributed on the market. Many studies have been conducted on functionality according to harvest time, and studies on Cornus officinalis' functionality and functional components have been conducted by harvest time, but research on immature fruit is insufficient. In addition, since Cornus officinalis is distributed with its seeds removed before the distribution process, Cornus officinalis seeds are simply discarded as farm waste.
이에, 본 발명자들은 산수유 미숙과가 항비만 효과가 있는 것을 확인하였으며, 산수유 씨앗을 포함한 미숙과에서 항비만 효과가 우수한 것을 확인하여, 본 발명을 완성하였다.Accordingly, the present inventors confirmed that unripe Cornus officinalis seeds have an anti-obesity effect, and that immature fruits including Cornus officinalis seeds have excellent anti-obesity effects, thereby completing the present invention.
본 발명의 목적은 산수유 추출물을 유효성분으로 포함하는, 비만 예방 또는 개선용 식품조성물을 제공하는 것이다.The purpose of the present invention is to provide a food composition for preventing or improving obesity, comprising Cornus officinalis extract as an active ingredient.
본 발명의 다른 목적은 산수유 추출물을 유효성분으로 포함하는, 비만 예방 또는 치료용 약학적 조성물을 제공하는 것이다.Another object of the present invention is to provide a pharmaceutical composition for preventing or treating obesity, comprising Cornus officinalis extract as an active ingredient.
본 발명의 또 다른 목적은 산수유를 세척하는 단계; 및Another object of the present invention is to wash Cornus officinalis; and
상기 세척된 산수유를 용매에 침지하는 단계;를 포함하는, 산수유 추출물의 제조 방법을 제공하는 것이다.To provide a method for producing Cornus officinalis extract, including the step of immersing the washed Cornus officinalis in a solvent.
본 발명의 또 다른 목적은 본 발명은 산수유를 세척하는 단계; 및Another object of the present invention is to wash Cornus officinalis; and
상기 세척된 산수유를 용매에 침지하는 단계;를 포함하는, 산수유 추출물에서, 갈릭산(gallic acid), 모로니사이드(Morroniside), 로가닌(Loganin), 베르베날린(Verbenalin), 스와로사이드(Sweroside) 및 콘누사이드(Cornuside)로 이루어진 군에서 선택된 기능성분을 증가시키는 방법을 제공하는 것이다.In the Cornus officinalis extract, including the step of immersing the washed Cornus officinalis in a solvent, gallic acid, Morroniside, Loganin, Verbenalin, and Swaroside To provide a method of increasing functional ingredients selected from the group consisting of Sweroside and Cornuside.
본 발명의 또 다른 목적은 시험관 내(in vitro)에서, 세포에 산수유 추출물을 처리하는 단계;를 포함하는, PPAR-γ, C/EBP-α 또는 C/EBP-β의 발현을 억제시키는 방법을 제공하는 것이다.Another object of the present invention is to provide a method for inhibiting the expression of PPAR-γ, C/EBP-α or C/EBP-β in vitro, comprising treating cells with Cornus officinalis extract. It is provided.
상기 목적을 달성하기 위하여, 본 발명은 산수유 추출물을 유효성분으로 포함하는, 비만 예방 또는 개선용 식품조성물을 제공한다.In order to achieve the above object, the present invention provides a food composition for preventing or improving obesity, comprising Cornus officinalis extract as an active ingredient.
또한, 본 발명은 산수유 추출물을 유효성분으로 포함하는, 비만 예방 또는 치료용 약학적 조성물을 제공한다.Additionally, the present invention provides a pharmaceutical composition for preventing or treating obesity, comprising Cornus officinalis extract as an active ingredient.
또한, 본 발명은 산수유를 세척하는 단계; 및In addition, the present invention includes the steps of washing Cornus officinalis; and
상기 세척된 산수유를 용매에 침지하는 단계;를 포함하는, 산수유 추출물의 제조 방법을 제공한다.It provides a method for producing Cornus officinalis extract, including the step of immersing the washed Cornus officinalis in a solvent.
또한, 본 발명은 산수유를 세척하는 단계; 및In addition, the present invention includes the steps of washing Cornus officinalis; and
상기 세척된 산수유를 용매에 침지하는 단계;를 포함하는, 산수유 추출물에서, 갈릭산(gallic acid), 모로니사이드(Morroniside), 로가닌(Loganin), 베르베날린(Verbenalin), 스와로사이드(Sweroside) 및 콘누사이드(Cornuside)로 이루어진 군에서 선택된 기능성분을 증가시키는 방법을 제공한다.In the Cornus officinalis extract, including the step of immersing the washed Cornus officinalis in a solvent, gallic acid, Morroniside, Loganin, Verbenalin, and Swaroside A method of increasing a functional ingredient selected from the group consisting of Sweroside and Cornuside is provided.
또한, 본 발명은 시험관 내(in vitro)에서, 세포에 산수유 추출물을 처리하는 단계;를 포함하는, PPAR-γ, C/EBP-α 또는 C/EBP-β의 발현을 억제시키는 방법을 제공한다.In addition, the present invention provides a method of inhibiting the expression of PPAR-γ, C/EBP-α or C/EBP-β in vitro, comprising treating cells with Cornus officinalis extract. .
본 발명은, 산수유 미성숙과 추출물이, 지방축적 억제 효과가 우수한 것을 확인하였으며, 지방 축적과 관련된 단백질의 발현을 억제시키는 것을 확인하였다. 또한, 산수유 미성숙과 추출물 중 씨앗을 포함한 추출물이, 과육 추출물보다 지방축적 및 지방 축적 단백질의 발현을 억제시키는 효과가 우수한 것을 확인하였으며, 산수유 미성숙과 추출물에서, 갈릭산(gallic acid), 모로니사이드(Morroniside), 로가닌(Loganin), 베르베날린(Verbenalin), 스와로사이드(Sweroside) 및 콘누사이드(Cornuside)의 함량이 증가된 것을 확인하여, 관련 산업에 유용하게 이용할 수 있다.The present invention confirmed that the extract of immature Cornus officinalis had an excellent effect in suppressing fat accumulation and suppressed the expression of proteins related to fat accumulation. In addition, it was confirmed that among the extracts of immature Cornus officinalis fruit, extracts containing seeds were more effective than pulp extracts in suppressing fat accumulation and the expression of fat accumulation proteins. In the extracts of immature Cornus officinalis fruit, gallic acid and moroniside were found. It was confirmed that the contents of Morroniside, Loganin, Verbenalin, Sweroside, and Cornuside were increased, so it can be usefully used in related industries.
도 1은 산수유 수확 시기별 외형을 나타낸 것이다.
도 2는 본 발명의 산수유(씨앗 포함) 및 산수유 과육 70% 주정 추출물의 세포 독성을 확인한 도이다.
Con: 무처리 대조군
VC: 용매만 처리한 대조군
F1 내지 F4: 수확 시기에 따른 산수유 과육 추출물
FS1 내지 FS4: 수확 시기에 따른 산수유(씨앗 포함) 추출물
도 3은 본 발명의 산수유 과육 70% 주정 추출물의 지방 축적 억제효과를 Oil red O 염색으로 확인한 도이다.
Con: 무처리 대조군(지방세포 분화와 지방축적을 유도하지 않은 그룹)
MDI: 3-isobutyl-1-methylxanthine, dexamethasone, insulin을 처리하여 지방세포 분화 및 지방축적을 유도한 그룹
F1 내지 F4: 수확 시기에 따른 산수유 과육 추출물을 처리한 그룹(지방세포 분화와 지방축적 유도 및 산수유 추출물을 함께 처리한 그룹)
도 4는 본 발명의 산수유(씨앗 포함) 70% 주정 추출물의 지방 축적 억제 효과를 Oil red O 염색으로 확인한 도이다.
Con: 무처리 대조군(지방세포 분화와 지방축적을 유도하지 않은 그룹)
MDI: 3-isobutyl-1-methylxanthine, dexamethasone, insulin을 처리하여 지방세포 분화 및 지방축적을 유도한 그룹
FS1 내지 FS4: 수확 시기에 따른 산수유(씨앗 포함) 추출물을 처리한 그룹 (지방세포 분화와 지방축적 유도 및 산수유 추출물을 함께 처리한 그룹)
도 5는 본 발명의 산수유(씨앗 포함) 및 산수유 과육 70% 주정 추출물의 Oil red O 염색 결과를 정량화한 도이다.
Con: 무처리 대조군(지방세포 분화와 지방축적을 유도하지 않은 그룹)
MDI: (3-isobutyl-1-methylxanthine, dexamethasone, insulin을 처리하여 지방세포 분화 및 지방축적을 유도한 그룹으로 산수유 추출물을 처리하지 않음)
F1 내지 F4: 수확 시기에 따른 산수유 과육 추출물을 처리한 그룹(지방세포 분화와 지방축적 유도 및 산수유 추출물을 함께 처리한 그룹)
FS1 내지 FS4: 수확 시기에 따른 산수유(씨앗 포함) 추출물을 처리한 그룹(지방세포 분화와 지방축적 유도 및 산수유 추출물을 함께 처리한 그룹)
도 6은 본 발명의 산수유(씨앗 포함) 및 산수유 과육 70% 주정 추출물의 지방축적 관련 단백질의 발현 조절을 웨스턴블랏으로 분석한 도이다.
Con: 무처리 대조군(지방세포 분화와 지방축적을 유도하지 않은 그룹)
MDI: 3-isobutyl-1-methylxanthine, dexamethasone, insulin을 처리하여 지방세포 분화 및 지방축적을 유도한 그룹
F1 내지 F4: 수확 시기에 따른 산수유 과육 추출물을 처리한 그룹(지방세포 분화와 지방축적 유도 및 산수유 추출물을 함께 처리한 그룹)
FS1 내지 FS4: 수확 시기에 따른 산수유(씨앗 포함) 추출물을 처리한 그룹 (지방세포 분화와 지방축적 유도 및 산수유 추출물을 함께 처리한 그룹)
도 7은 본 발명의 산수유(씨앗 포함) 및 산수유 과육 70% 주정 추출물의 PPAR-γ 발현 억제효과를 정량화한 것이다.
Con: 무처리 대조군(지방세포 분화와 지방축적을 유도하지 않은 그룹)
MDI: 3-isobutyl-1-methylxanthine, dexamethasone, insulin을 처리하여 지방세포 분화 및 지방축적을 유도한 그룹
F1 및 F3: 수확 시기(9월 및 11월)에 따른 산수유 과육 추출물을 처리한 그룹(지방세포 분화와 지방축적 유도 및 산수유 추출물을 함께 처리한 그룹)
FS1 및 FS3: 수확 시기(9월 및 11월)에 따른 산수유(씨앗 포함) 추출물을 처리한 그룹(지방세포 분화와 지방축적 유도 및 산수유 추출물을 함께 처리한 그룹)
도 8은 본 발명의 산수유(씨앗 포함) 및 산수유 과육 70% 주정 추출물의 C/EBP-α 발현 억제효과를 정량화한 것이다.
Con: 무처리 대조군(지방세포 분화와 지방축적을 유도하지 않은 그룹)
MDI: 3-isobutyl-1-methylxanthine, dexamethasone, insulin을 처리하여 지방세포 분화 및 지방축적을 유도한 그룹
F1 및 F3: 수확 시기(9월 및 11월)에 따른 산수유 과육 추출물을 처리한 그룹(지방세포 분화와 지방축적 유도 및 산수유 추출물을 함께 처리한 그룹)
FS1 및 FS3: 수확 시기(9월 및 11월)에 따른 산수유(씨앗 포함) 추출물을 처리한 그룹(지방세포 분화와 지방축적 유도 및 산수유 추출물을 함께 처리한 그룹)
도 9는 본 발명의 산수유(씨앗 포함) 및 산수유 과육 70% 주정 추출물의 C/EBP-α=β 발현 억제효과를 정량화한 것이다.
Con: 지방세포 분화와 지방축적을 유도하지 않은 그룹
MDI: 3-isobutyl-1-methylxanthine, dexamethasone, insulin을 처리하여 지방세포 분화 및 지방축적을 유도한 그룹
F1 및 F3: 수확 시기(9월 및 11월)에 따른 산수유 과육 추출물을 처리한 그룹(지방세포 분화와 지방축적 유도 및 산수유 추출물을 함께 처리한 그룹)
FS1 및 FS3: 수확 시기(9월 및 11월)에 따른 산수유(씨앗 포함) 추출물을 처리한 그룹(지방세포 분화와 지방축적 유도 및 산수유 추출물을 함께 처리한 그룹)
도 10은 본 발명의 산수유(씨앗 포함) 및 산수유 과육 추출물의 추출 용매에 따른 세포 독성을 확인한 도이다.
Con: 무처리 대조군
VC: 용매만 처리한 대조군
F1 W 및 F3 W: 수확 시기(9월 및 11월)에 따른 산수유 과육 물 추출물
FS1 W 및 FS3 W: 수확 시기(9월 및 11월)에 따른 산수유(씨앗 포함) 물 추출물
F1 E 및 F3 E: 수확 시기(9월 및 11월)에 따른 산수유 과육 70% 주정 추출물
FS1 E 및 FS3 E: 수확 시기(9월 및 11월)에 따른 산수유(씨앗 포함) 70% 주정 추출물
도 11은 본 발명의 산수유(씨앗 포함) 및 산수유 과육 추출물의 추출 용매에 따른 지방 축적 억제효과를 Oil red O 염색으로 확인하여 정량화한 것이다.
Con: 무처리 대조군
VC: 용매만 처리한 대조군
F1 W 및 F3 W: 수확 시기(9월 및 11월)에 따른 산수유 과육 물 추출물
FS1 W 및 FS3 W: 수확 시기(9월 및 11월)에 따른 산수유(씨앗 포함) 물 추출물
F1 E 및 F3 E: 수확 시기(9월 및 11월)에 따른 산수유 과육 70% 주정 추출물
FS1 E 및 FS3 E: 수확 시기(9월 및 11월)에 따른 산수유(씨앗 포함) 70% 주정 추출물
도 12는 본 발명의 산수유(씨앗 포함) 및 산수유 과육 추출물의 유효성분인 갈릭산(gallic acid)의 함량을 확인한 도이다.
도 13은 본 발명의 산수유(씨앗 포함) 및 산수유 과육 추출물의 유효성분인 모로니사이드(Morroniside)의 함량을 확인한 도이다.
도 14는 본 발명의 산수유(씨앗 포함) 및 산수유 과육 추출물의 유효성분인 로가닌(Loganin)의 함량을 확인한 도이다.
도 15는 본 발명의 산수유(씨앗 포함) 및 산수유 과육 추출물의 유효성분인 베르베나림(Verbenalim)의 함량을 확인한 도이다.
도 16은 본 발명의 산수유(씨앗 포함) 및 산수유 과육 추출물의 유효성분인 스와로사이드(Sweroside)의 함량을 확인한 도이다.
도 17은 본 발명의 산수유(씨앗 포함) 및 산수유 과육 추출물의 유효성분인 콘누사이드(Cornuside)의 함량을 확인한 도이다.Figure 1 shows the appearance of Cornus officinalis by harvest time.
Figure 2 is a diagram confirming the cytotoxicity of Cornus officinalis (including seeds) and 70% alcohol extract of Cornus officinalis pulp of the present invention.
Con: untreated control
VC: Control group treated with solvent only
F1 to F4: Cornus officinalis pulp extract according to harvest time
FS1 to FS4: Cornus officinalis (including seeds) extract according to harvest time
Figure 3 is a diagram confirming the fat accumulation inhibition effect of the 70% alcohol extract of Cornus officinalis pulp of the present invention by Oil red O staining.
Con: Untreated control group (group in which adipocyte differentiation and fat accumulation were not induced)
MDI: Group treated with 3-isobutyl-1-methylxanthine, dexamethasone, and insulin to induce adipocyte differentiation and fat accumulation.
F1 to F4: Group treated with Cornus officinalis pulp extract according to harvest time (group treated with Cornus officinalis extract inducing adipocyte differentiation and fat accumulation)
Figure 4 is a diagram confirming the fat accumulation inhibition effect of the 70% alcohol extract of Cornus officinalis (including seeds) of the present invention by Oil red O staining.
Con: Untreated control group (group in which adipocyte differentiation and fat accumulation were not induced)
MDI: Group treated with 3-isobutyl-1-methylxanthine, dexamethasone, and insulin to induce adipocyte differentiation and fat accumulation.
FS1 to FS4: Group treated with Cornus officinalis (including seeds) extract according to harvest time (group treated with Cornus officinalis extract inducing adipocyte differentiation and fat accumulation)
Figure 5 is a diagram quantifying the Oil red O staining results of Cornus officinalis (including seeds) and 70% alcohol extract of Cornus officinalis pulp of the present invention.
Con: Untreated control group (group in which adipocyte differentiation and fat accumulation were not induced)
MDI: (group treated with 3-isobutyl-1-methylxanthine, dexamethasone, and insulin to induce adipocyte differentiation and fat accumulation; cornelian cherry extract was not treated)
F1 to F4: Group treated with Cornus officinalis pulp extract according to harvest time (group treated with Cornus officinalis extract inducing adipocyte differentiation and fat accumulation)
FS1 to FS4: Group treated with extract of Cornus officinalis (including seeds) according to harvest time (group treated with induction of adipocyte differentiation and fat accumulation and treatment with Cornus officinalis extract)
Figure 6 is a diagram showing the control of expression of proteins related to fat accumulation in Cornelian cherry (including seeds) and 70% alcohol extract of cornelian cherry pulp according to the present invention, analyzed by Western blot.
Con: Untreated control group (group in which adipocyte differentiation and fat accumulation were not induced)
MDI: Group treated with 3-isobutyl-1-methylxanthine, dexamethasone, and insulin to induce adipocyte differentiation and fat accumulation.
F1 to F4: Group treated with Cornus officinalis pulp extract according to harvest time (group treated with Cornus officinalis extract inducing adipocyte differentiation and fat accumulation)
FS1 to FS4: Group treated with Cornus officinalis (including seeds) extract according to harvest time (group treated with Cornus officinalis extract inducing adipocyte differentiation and fat accumulation)
Figure 7 quantifies the inhibitory effect of PPAR-γ expression of Cornus officinalis (including seeds) and 70% alcohol extract of Cornus officinalis pulp of the present invention.
Con: Untreated control group (group in which adipocyte differentiation and fat accumulation were not induced)
MDI: Group treated with 3-isobutyl-1-methylxanthine, dexamethasone, and insulin to induce adipocyte differentiation and fat accumulation.
F1 and F3: Groups treated with Cornus officinalis pulp extract according to harvest time (September and November) (group treated with Cornus officinalis extract and induced adipocyte differentiation and fat accumulation)
FS1 and FS3: Group treated with Cornus officinalis (including seeds) extract according to harvest time (September and November) (group treated with Cornus officinalis extract and induced adipocyte differentiation and fat accumulation)
Figure 8 quantifies the inhibitory effect of C/EBP-α expression of Cornus officinalis (including seeds) and 70% alcohol extract of Cornus officinalis pulp of the present invention.
Con: Untreated control group (group in which adipocyte differentiation and fat accumulation were not induced)
MDI: Group treated with 3-isobutyl-1-methylxanthine, dexamethasone, and insulin to induce adipocyte differentiation and fat accumulation.
F1 and F3: Groups treated with Cornus officinalis pulp extract according to harvest time (September and November) (group treated with Cornus officinalis extract and induced adipocyte differentiation and fat accumulation)
FS1 and FS3: Group treated with Cornus officinalis (including seeds) extract according to harvest time (September and November) (group treated with Cornus officinalis extract and induced adipocyte differentiation and fat accumulation)
Figure 9 quantifies the inhibitory effect of C/EBP-α=β expression of Cornus officinalis (including seeds) and 70% alcohol extract of Cornus officinalis pulp of the present invention.
Con: Group in which adipocyte differentiation and fat accumulation were not induced.
MDI: Group treated with 3-isobutyl-1-methylxanthine, dexamethasone, and insulin to induce adipocyte differentiation and fat accumulation.
F1 and F3: Groups treated with Cornus officinalis pulp extract according to harvest time (September and November) (group treated with Cornus officinalis extract and induced adipocyte differentiation and fat accumulation)
FS1 and FS3: Group treated with Cornus officinalis (including seeds) extract according to harvest time (September and November) (group treated with Cornus officinalis extract and induced adipocyte differentiation and fat accumulation)
Figure 10 is a diagram confirming the cytotoxicity of Cornus officinalis (including seeds) and Cornus officinalis pulp extract according to the extraction solvent of the present invention.
Con: untreated control
VC: Control group treated with solvent only
F1 W and F3 W: Cornus officinalis pulp water extract according to harvest time (September and November)
FS1 W and FS3 W: Cornus officinalis (including seeds) water extract according to harvest time (September and November)
F1 E and F3 E: 70% alcohol extract of Cornus officinalis pulp according to harvest time (September and November)
FS1 E and FS3 E: Cornus officinalis (including seeds) 70% alcohol extract according to harvest time (September and November)
Figure 11 is a quantification of the fat accumulation inhibition effect according to the extraction solvent of Cornus officinalis (including seeds) and Cornus officinalis pulp extract of the present invention confirmed by Oil red O staining.
Con: untreated control
VC: Control group treated with solvent only
F1 W and F3 W: Cornus officinalis pulp water extract according to harvest time (September and November)
FS1 W and FS3 W: Cornus officinalis (including seeds) water extract according to harvest time (September and November)
F1 E and F3 E: 70% alcohol extract of Cornus officinalis pulp according to harvest time (September and November)
FS1 E and FS3 E: Cornus officinalis (including seeds) 70% alcohol extract according to harvest time (September and November)
Figure 12 is a diagram confirming the content of gallic acid, an active ingredient of Cornus officinalis (including seeds) and Cornus officinalis pulp extract of the present invention.
Figure 13 is a diagram confirming the content of Morroniside, an active ingredient of Cornus officinalis (including seeds) and Cornus officinalis pulp extract of the present invention.
Figure 14 is a diagram confirming the content of Loganin, an active ingredient in Cornus officinalis (including seeds) and Cornus officinalis pulp extract of the present invention.
Figure 15 is a diagram confirming the content of Verbenalim, an active ingredient of Cornus officinalis (including seeds) and Cornus officinalis pulp extract of the present invention.
Figure 16 is a diagram confirming the content of Sweroside, an active ingredient in Cornus officinalis (including seeds) and Cornus officinalis pulp extract of the present invention.
Figure 17 is a diagram confirming the content of Cornuside, an active ingredient in Cornus officinalis (including seeds) and Cornus officinalis pulp extract of the present invention.
이하 첨부된 도면을 참조하여 본 발명의 실시예들을 상세히 설명한다. 이하의 설명에 있어, 당업자에게 주지 저명한 기술에 대해서는 그 상세한 설명을 생략할 수 있다. 또한, 본 발명을 설명함에 있어서, 관련된 공지 기능 또는 구성에 대한 구체적인 설명이 본 발명의 요지를 불필요하게 흐릴 수 있다고 판단되는 경우에는 그 상세한 설명을 생략할 수 있다. 또한, 본 명세서에서 사용되는 용어(terminology)들은 본 발명의 바람직한 실시예를 적절히 표현하기 위해 사용된 용어들로서, 이는 사용자, 운용자의 의도 또는 본 발명이 속하는 분야의 관례 등에 따라 달라질 수 있다.Hereinafter, embodiments of the present invention will be described in detail with reference to the attached drawings. In the following description, detailed descriptions of techniques well known to those skilled in the art may be omitted. Additionally, when describing the present invention, if it is determined that a detailed description of a related known function or configuration may unnecessarily obscure the gist of the present invention, the detailed description may be omitted. In addition, the terminology used in this specification is a term used to appropriately express preferred embodiments of the present invention, and may vary depending on the intention of the user or operator or the customs of the field to which the present invention belongs.
따라서 본 용어들에 대한 정의는 본 명세서 전반에 걸친 내용을 토대로 내려져야 할 것이다. 명세서 전체에서, 어떤 부분이 어떤 구성요소를 "포함"한다고 할 때, 이는 특별히 반대되는 기재가 없는 한 다른 구성요소를 제외하는 것이 아니라 다른 구성 요소를 더 포함할 수 있는 것을 의미한다.Therefore, definitions of these terms should be made based on the content throughout this specification. Throughout the specification, when a part is said to “include” a certain element, this means that it may further include other elements rather than excluding other elements, unless specifically stated to the contrary.
본 발명은 산수유 추출물을 유효성분으로 포함하는, 비만 예방 또는 개선용 식품조성물을 제공한다.The present invention provides a food composition for preventing or improving obesity, comprising Cornus officinalis extract as an active ingredient.
본 발명에서 사용되는 용어 “예방”은 본 발명의 조성물의 투여로 특정 질환의 증상을 억제하거나 진행을 지연시키는 모든 행위를 의미한다.The term “prevention” used in the present invention refers to any action that suppresses the symptoms or delays the progression of a specific disease by administering the composition of the present invention.
본 발명에서 사용되는 용어 “개선”은 치료되는 상태와 관련된 파라미터, 예를 들면 증상의 정도를 적어도 감소시키는 모든 행위를 의미한다.As used herein, the term “improvement” refers to any action that reduces at least the severity of a parameter, such as a symptom, related to the condition being treated.
본 발명의 식품 조성물은 본 발명의 유효성분을 함유하는 것 외에 통상의 식품 조성물과 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다.In addition to containing the active ingredient of the present invention, the food composition of the present invention may contain various flavoring agents or natural carbohydrates as additional ingredients like a typical food composition.
상술한 천연 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스 등; 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당, 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 상술한 향미제는 천연 향미제 (타우마틴), 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진 등) 및 합성 향미제 (사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. 본 발명의 식품 조성물은 상기 약학적 조성물과 동일한 방식으로 제제화되어 기능성 식품으로 이용하거나, 각종 식품에 첨가할 수 있다. 본 발명의 조성물을 첨가할 수 있는 식품으로는 예를 들어, 음료류, 육류, 초코렛, 식품류, 과자류, 피자, 라면, 기타 면류, 껌류, 사탕류, 아이스크림류, 알코올 음료류, 비타민 복합제 및 건강보조식품류 등이 있다.Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose, etc.; Disaccharides such as maltose, sucrose, etc.; and polysaccharides, such as common sugars such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. The above-described flavoring agents include natural flavoring agents (thaumatin), stevia extracts (e.g. rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.). The food composition of the present invention can be formulated in the same way as the pharmaceutical composition and used as a functional food or added to various foods. Foods to which the composition of the present invention can be added include, for example, beverages, meat, chocolate, foods, confectionery, pizza, ramen, other noodles, gum, candy, ice cream, alcoholic beverages, vitamin complexes, health supplements, etc. There is.
또한 상기 식품 조성물은 유효성분인 추출물 외에 여러 가지 영양제, 비타민, 광물 (전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제 (치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 그밖에 본 발명의 식품 조성물은 천연 과일 쥬스 및 과일 쥬스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다.In addition to the extract as an active ingredient, the food composition contains various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic and natural flavors, colorants and thickening agents (cheese, chocolate, etc.), pectic acid and its salts, It may contain alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc. In addition, the food composition of the present invention may contain pulp for the production of natural fruit juice, fruit juice beverages, and vegetable beverages.
본 발명의 기능성 식품 조성물은 비만의 예방 또는 치료 목적으로, 정제, 캅셀, 분말, 과립, 액상, 환 등의 형태로 제조 및 가공될 수 있다. 본 발명에서 '건강기능성 식품 조성물'이라 함은 건강기능식품에 관한 법률 제6727호에 따른 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 제조 및 가공한 식품을 말하며, 인체의 구조 및 기능에 대하여 영양소를 조절하거나 생리학적 작용 등과 같은 보건용도에 유용한 효과를 얻을 목적으로 섭취하는 것을 의미한다. 본 발명의 건강기능식품은 통상의 식품 첨가물을 포함할 수 있으며, 식품 첨가물로서의 적합 여부는 다른 규정이 없는 한, 식품의약품안전청에 승인된 식품 첨가물 공전의 총칙 및 일반시험법 등에 따라 해당 품목에 관한 규격 및 기준에 의하여 판정한다. 상기 '식품 첨가물 공전'에 수재된 품목으로는 예를 들어, 케톤류, 글리신, 구연산칼슘, 니코틴산, 계피산 등의 화학적 합성물; 감색소, 감초추출물, 결정셀룰로오스, 고량색소, 구아검 등의 천연첨가물; L-글루타민산나트륨 제제, 면류첨가알칼리제, 보존료 제제, 타르색소제제 등의 혼합제제류 등을 들 수 있다. 예를 들어, 정제 형태의 건강기능식품은 본 발명의 유효성분을 부형제, 결합제, 붕해제 및 다른 첨가제와 혼합한 혼합물을 통상의 방법으로 과립화한 다음, 활택제 등을 넣어 압축성형하거나, 상기 혼합물을 직접 압축 성형할 수 있다. 또한 상기 정제 형태의 건강기능식품은 필요에 따라 교미제 등을 함유할 수도 있다. 캅셀 형태의 건강기능식품 중 경질 캅셀제는 통상의 경질 캅셀에 본 발명의 유효성분을 부형제 등의 첨가제와 혼합한 혼합물을 충진하여 제조할 수 있으며, 연질 캅셀제는 본 발명의 유효성분을 부형제 등의 첨가제와 혼합한 혼합물을 젤라틴과 같은 캅셀기제에 충진하여 제조할 수 있다. 상기 연질 캅셀제는 필요에 따라 글리세린 또는 소르비톨 등의 가소제, 착색제, 보존제 등을 함유할 수 있다. 환 형태의 건강기능식품은 본 발명의 유효성분과 부형제, 결합제, 붕해제 등을 혼합한 혼합물을 기존에 공지된 방법으로 성형하여 조제할 수 있으며, 필요에 따라 백당이나 다른 제피제로 제피할 수 있으며, 또는 전분, 탈크와 같은 물질로 표면을 코팅할 수도 있다. 과립 형태의 건강기능식품은 본 발명의 유효성분의 부형제, 결합제, 붕해제 등을 혼합한 혼합물을 기존에 공지된 방법으로 입상으로 제조할 수 있으며, 필요에 따라 착향제, 교미제 등을 함유할 수 있다.The functional food composition of the present invention can be manufactured and processed in the form of tablets, capsules, powders, granules, liquids, pills, etc. for the purpose of preventing or treating obesity. In the present invention, 'health functional food composition' refers to food manufactured and processed using raw materials or ingredients with functionality useful to the human body in accordance with Act No. 6727 on Health Functional Food, and refers to food that is related to the structure and function of the human body. It means taking it for the purpose of controlling nutrients or obtaining useful health effects such as physiological effects. The health functional food of the present invention may contain common food additives, and its suitability as a food additive is determined in accordance with the general provisions and general test methods of the food additive code approved by the Food and Drug Administration, unless otherwise specified. Judgment is made according to specifications and standards. Items listed in the 'Food Additive Code' include, for example, chemical compounds such as ketones, glycine, calcium citrate, nicotinic acid, and cinnamic acid; Natural additives such as dark pigment, licorice extract, crystalline cellulose, high-quality pigment, and guar gum; Examples include mixed preparations such as sodium L-glutamate preparations, noodle additive alkaline preparations, preservative preparations, and tar coloring preparations. For example, the health functional food in the form of a tablet is made by granulating a mixture of the active ingredient of the present invention with excipients, binders, disintegrants and other additives in a conventional manner, and then adding a lubricant and compression molding, or The mixture can be directly compression molded. In addition, the health functional food in the form of tablets may contain flavoring agents, etc., if necessary. Among capsule-type health functional foods, hard capsules can be manufactured by filling a regular hard capsule with a mixture of the active ingredient of the present invention mixed with additives such as excipients, and soft capsules can be prepared by mixing the active ingredient of the present invention with additives such as excipients. It can be manufactured by filling the mixture with a capsule base such as gelatin. The soft capsule may contain plasticizers such as glycerin or sorbitol, colorants, preservatives, etc., if necessary. The health functional food in the form of a pill can be prepared by molding a mixture of the active ingredient of the present invention and excipients, binders, disintegrants, etc., using a known method. If necessary, it can be coated with white sugar or other coating agent. Alternatively, the surface can be coated with substances such as starch or talc. Health functional food in the form of granules can be manufactured into granules by mixing a mixture of excipients, binders, disintegrants, etc. of the active ingredients of the present invention by a known method, and may contain flavoring agents, flavoring agents, etc., if necessary. You can.
본 발명의 일실시예에 따르면, 상기 산수유는, 미숙과(immature fruit)인 것일 수 있고, 씨앗(seed)를 더 포함하는 것일 수 있다.According to one embodiment of the present invention, the Cornus officinalis may be an immature fruit and may further include seeds.
본 발명의 “미숙과(immature fruit)”는 완전히 성숙되지 않은 열매를 뜻하며, 본 발명에서는 산수유 미숙과를 뜻한다. 일반적으로 산수유는 11월경에 채취되는 완숙과를 이용하나, 본 발명의 산수유 미숙과는 9월경에 채취되어, 산수유가 붉어지기 전의 열매를 뜻한다.“Immature fruit” in the present invention refers to a fruit that is not fully mature, and in the present invention, it refers to the immature fruit of Cornus officinalis. Generally, Cornus officinalis uses ripe fruits collected around November, but the immature Cornus officinalis fruits of the present invention are collected around September and refer to fruits before the Cornus officinalis turns red.
본 발명의 일실시예에 따르면, 상기 추출물은 물, C1 내지 C4의 저급 알코올, 저급 알코올 수용액, 핵산, 클로로포름 및 아세톤으로 이루어진 군에서 선택된 용매인 것일 수 있으며, 바람직하게는 물 또는 저급알코올 수용액이나, 이에 제한되지는 않는다.According to one embodiment of the present invention, the extract may be a solvent selected from the group consisting of water, C1 to C4 lower alcohol, aqueous lower alcohol solution, nucleic acid, chloroform, and acetone, and is preferably water or an aqueous lower alcohol solution. , but is not limited to this.
본 발명의 일실시예에 따르면, 상기 추출물은 산수유 및 용매가 1 : 20의 중량비로 혼합되어 추출되는 것일 수 있다.According to one embodiment of the present invention, the extract may be extracted by mixing Cornus officinalis and a solvent at a weight ratio of 1:20.
본 발명의 일실시예에 따르면, 상기 추출물은 지방 축적을 억제하는 것일 수 있다.According to one embodiment of the present invention, the extract may inhibit fat accumulation.
본 발명의 일실시예에 따르면, 상기 추출물은, 지방 합성 인자의 발현을 억제시키는 것일 수 있으며, 상기 지방 합성 인자는, PPAR-γ, C/EBP-α 또는 C/EBP-β인 것일 수 있다.According to one embodiment of the present invention, the extract may inhibit the expression of a fat synthesis factor, and the fat synthesis factor may be PPAR-γ, C/EBP-α, or C/EBP-β. .
본 발명의 일실시예에 따르면, 상기 추출물은, 갈릭산(gallic acid), 모로니사이드(Morroniside), 로가닌(Loganin), 베르베날린(Verbenalin), 스와로사이드(Sweroside) 및 콘누사이드(Cornuside)로 이루어진 군에서 선택된 기능성분의 함량이 증가된 것일 수 있다.According to one embodiment of the present invention, the extract includes gallic acid, Morroniside, Loganin, Verbenalin, Sweroside, and Cornuside. The content of the functional ingredient selected from the group consisting of (Cornuside) may be increased.
또한, 본 발명은 산수유 추출물을 유효성분으로 포함하는, 비만 예방 또는 치료용 약학적 조성물을 제공한다.Additionally, the present invention provides a pharmaceutical composition for preventing or treating obesity, comprising Cornus officinalis extract as an active ingredient.
본 발명에서 사용되는 용어 “치료”는 본 발명의 조성물의 투여로 특정 질환의 증상을 호전 또는 이롭게 변경시키는 모든 행위를 의미한다.The term “treatment” used in the present invention refers to any action that improves or beneficially changes the symptoms of a specific disease by administering the composition of the present invention.
본 발명의 약학 조성물에는 유효성분 이외에 보조제(adjuvant)를 추가로 포함할 수 있다. 상기 보조제는 당해 기술분야에 알려진 것이라면 어느 것이나 제한 없이 사용할 수 있으나, 예를 들어 프로인트(Freund)의 완전 보조제 또는 불완전 보조제를 더 포함하여 그 효과를 증가시킬 수 있다.The pharmaceutical composition of the present invention may further include adjuvants in addition to the active ingredients. The auxiliary agent may be any one known in the art without limitation, but the effect may be increased by further including, for example, Freund's complete auxiliary agent or incomplete auxiliary agent.
본 발명에 따른 약학 조성물은 유효성분을 약학적으로 허용된 담체에 혼입시킨 형태로 제조될 수 있다. 여기서, 약학적으로 허용된 담체는 제약 분야에서 통상 사용되는 담체, 부형제 및 희석제를 포함한다. 본 발명의 약학 조성물에 이용할 수 있는 약학적으로 허용된 담체는 이들로 제한되는 것은 아니지만, 락토스, 덱스트로스, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로스, 메틸 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다.The pharmaceutical composition according to the present invention can be prepared by incorporating the active ingredient into a pharmaceutically acceptable carrier. Here, pharmaceutically acceptable carriers include carriers, excipients, and diluents commonly used in the pharmaceutical field. Pharmaceutically acceptable carriers that can be used in the pharmaceutical composition of the present invention include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, Examples include calcium phosphate, calcium silicate, cellulose, methyl cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
본 발명의 약학 조성물은 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀전, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 또는 멸균 주사용액의 형태로 제형화하여 사용될 수 있다.The pharmaceutical composition of the present invention can be formulated and used in the form of oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories, or sterile injection solutions according to conventional methods. .
제제화할 경우에는 통상 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제될 수 있다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 그러한 고형 제제는 유효성분에 적어도 하나 이상의 부형제, 예를 들면 전분, 칼슘 카르보네이트, 수크로스, 락토오스, 젤라틴 등을 섞어 조제될 수 있다. 또한, 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용될 수 있다. 경구투여를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데, 일반적으로 사용되는 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수용성용제, 현탁제, 유제, 동결건조 제제 및 좌제가 포함된다. 비수용성용제, 현탁제로는 프로필렌 글리콜, 폴리에틸렌 글리콜, 올리브유와 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 트윈(tween) 61, 카카오지, 라우린지, 글리세로젤라틴 등이 사용될 수 있다.When formulated, it can be prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and such solid preparations contain the active ingredient plus at least one excipient, such as starch, calcium carbonate, sucrose, lactose, and gelatin. It can be prepared by mixing etc. Additionally, in addition to simple excipients, lubricants such as magnesium stearate and talc can also be used. Liquid preparations for oral administration include suspensions, oral solutions, emulsions, and syrups. In addition to the commonly used diluents such as water and liquid paraffin, they contain various excipients such as wetting agents, sweeteners, fragrances, and preservatives. You can. Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations, and suppositories. Non-aqueous solvents and suspensions include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate. As a base for suppositories, witepsol, tween 61, cacao, laurel, glycerogelatin, etc. can be used.
본 발명에 따른 약학 조성물은 개체에 다양한 경로로 투여될 수 있다. 투여의 모든 방식이 예상될 수 있는데, 예를 들면 경구, 정맥, 근육, 피하, 복강내 주사에 의해 투여될 수 있다.The pharmaceutical composition according to the present invention can be administered to an individual through various routes. All modes of administration are contemplated, for example, by oral, intravenous, intramuscular, subcutaneous, or intraperitoneal injection.
본 발명에 따른 약학 조성물의 투여량은 개체의 연령, 체중, 성별, 신체 상태 등을 고려하여 선택된다. 상기 약학 조성물 중 포함되는 유효성분의 농도는 대상에 따라 다양하게 선택할 수 있음은 자명하며, 바람직하게는 약학 조성물에0.01 ~ 5,000 ㎍/ml의 농도로 포함되는 것이다. 그 농도가 0.01 ㎍/ml 미만일 경우에는 약학 활성이 나타나지 않을 수 있고, 5,000 ㎍/ml를 초과할 경우에는 인체에 독성을 나타낼 수 있다.The dosage of the pharmaceutical composition according to the present invention is selected taking into account the age, weight, gender, physical condition, etc. of the individual. It is obvious that the concentration of the active ingredient included in the pharmaceutical composition can be selected in various ways depending on the target, and is preferably included in the pharmaceutical composition at a concentration of 0.01 to 5,000 μg/ml. If the concentration is less than 0.01 ㎍/ml, pharmaceutical activity may not appear, and if it exceeds 5,000 ㎍/ml, it may be toxic to the human body.
또한, 본 발명은 산수유를 세척하는 단계; 및In addition, the present invention includes the steps of washing Cornus officinalis; and
상기 세척된 산수유를 용매에 침지하는 단계;를 포함하는, 산수유 추출물의 제조 방법을 제공한다.It provides a method for producing Cornus officinalis extract, including the step of immersing the washed Cornus officinalis in a solvent.
또한, 본 발명은 산수유를 세척하는 단계; 및In addition, the present invention includes the steps of washing Cornus officinalis; and
상기 세척된 산수유를 용매에 침지하는 단계;를 포함하는, 산수유 추출물에서, 갈릭산(gallic acid), 모로니사이드(Morroniside), 로가닌(Loganin), 베르베날린(Verbenalin), 스와로사이드(Sweroside) 및 콘누사이드(Cornuside)로 이루어진 군에서 선택된 기능성분을 증가시키는 방법을 제공한다.In the Cornus officinalis extract, including the step of immersing the washed Cornus officinalis in a solvent, gallic acid, Morroniside, Loganin, Verbenalin, and Swaroside A method of increasing a functional ingredient selected from the group consisting of Sweroside and Cornuside is provided.
또한, 본 발명은 시험관 내(in vitro)에서, 세포에 산수유 추출물을 처리하는 단계;를 포함하는, PPAR-γ, C/EBP-α 또는 C/EBP-β의 발현을 억제시키는 방법을 제공한다.In addition, the present invention provides a method of inhibiting the expression of PPAR-γ, C/EBP-α or C/EBP-β in vitro, comprising treating cells with Cornus officinalis extract. .
이하, 본 발명을 실시예에 의하여 더욱 상세하게 설명한다. 이들 실시예는 단지 본 발명을 보다 구체적으로 설명하기 위한 것으로, 본 발명의 범위가 이들 실시예에 국한되지 않는다는 것은 당업계에서 통상의 지식을 가진 자에게 있어서 자명할 것이다.Hereinafter, the present invention will be described in more detail by examples. These examples are only for illustrating the present invention in more detail, and it will be apparent to those skilled in the art that the scope of the present invention is not limited to these examples.
<실시예 1> 수확 시기별 산수유 추출물의 제조<Example 1> Preparation of Cornus officinalis extract according to harvest time
본 발명의 조건에 따른 산수유 추출물을 제조하기 위하여, 9월(미숙과), 10월, 11월 및 12월에 수확된 산수유를 준비하였다(도 1). 그 후 산수유를 씨를 포함한 것(FS)과, 씨를 제거하고 과육만 분리한 군(F)으로 각각 분류하였다. 그 후 각각의 산수유 군을 70% 주정 또는 물을 용매로 이용하여 추출하였다. 산수유 과육만 추출한 추출물은 수확 시기(9월 내지 12월)에 따라서, F1, F2, F3 및 F4로 분류하였으며, 씨를 포함한 산수유 추출물은 수확 시기에 따라서(9월 내지 12월) FS1, FS2, FS3 및 FS4로 분류하였다. 산수유 추출에서 산수유와 용매 혼합비는 1 : 20의 중량비로 혼합하여 추출하였다.To prepare Cornus officinalis extract according to the conditions of the present invention, Cornus officinalis harvested in September (immature fruit), October, November, and December was prepared (Figure 1). Afterwards, Cornus officinalis was classified into those containing seeds (FS) and those with seeds removed and only the pulp separated (F). Afterwards, each Cornus officinalis group was extracted using 70% alcohol or water as a solvent. Extracts containing only Cornus officinalis pulp were classified into F1, F2, F3, and F4 according to harvest time (September to December), and extracts of Cornus officinalis containing seeds were classified into FS1, FS2, and FS3 depending on harvest time (September to December). and FS4. In the extraction of Cornus officinalis, Cornus officinalis and solvent were mixed at a weight ratio of 1:20.
<실시예 2> 산수유 추출물의 세포 독성 확인<Example 2> Confirmation of cytotoxicity of Cornus officinalis extract
본 발명의 산수유 추출물의 세포 독성을 확인하기 위하여, 상기 실시예 1에서 수득된 산수유 추출물 중 70% 주정 추출물을 이용하여, 세포 독성을 확인하였다. 구체적으로, 3T3-L1 세포주를 이용하여 세포 독성을 평가하였으며, MTT assay로 세포 생존율을 분석하였다. 분화되지 않은 3T3-L1 세포는 104∼105 cells/mL로 증식시킨 후 대조군으로는 아무것도 처리하지 않은 con 군과, 용매만을 처리한 Vehicle(VC)군을 이용하였다. 처리구는 동일한 조건에서 각각의 추출물을 농도별로 처리하였다. 모든 처리군은 MTT 시약을 이용하여 처리하고 발색 후 DMSO(dimetyl-sulfoxide)를 이용하여 재용해하고 microplate reader에서 540 nm로 측정하여 Vehicle(VC) 대비 세포 생존율로서 나타내었다.In order to confirm the cytotoxicity of the Cornus officinalis extract of the present invention, 70% alcohol extract of the Cornus officinalis extract obtained in Example 1 was used to confirm the cytotoxicity. Specifically, cytotoxicity was evaluated using the 3T3-L1 cell line, and cell viability was analyzed using the MTT assay. Undifferentiated 3T3-L1 cells were proliferated to 10 4 ∼ 10 5 cells/mL, and then the con group, which was not treated with anything, and the Vehicle (VC) group, which was treated only with solvent, were used as control groups. In the treatment group, each extract was treated at different concentrations under the same conditions. All treatment groups were treated using MTT reagent, re-dissolved using DMSO (dimetyl-sulfoxide) after color development, measured at 540 nm in a microplate reader, and expressed as cell viability compared to Vehicle (VC).
그 결과, 도 2에 나타낸 바와 같이, 본 발명의 산수유 추출물은 세포에 독성을 나타내지 않는 것을 확인하였다.As a result, as shown in Figure 2, it was confirmed that the Cornus officinalis extract of the present invention was not toxic to cells.
<실시예 3> 산수유 추출물의 항비만 활성 확인<Example 3> Confirmation of anti-obesity activity of Cornus officinalis extract
<3-1> 산수유 추출물의 지방축적 억제 확인<3-1> Confirmation of inhibition of fat accumulation by Cornus officinalis extract
본 발명의 산수유 추출물들의 항비만 활성을 확인하였다. 구체적으로, 3T3-L1 세포주에서 상기 실시예 1에서 제조된 산수유 추출물의 항비만 효과를 Oil red 염색으로 평가하였다. 구체적으로 Oil red-O assay는 3T3-L1 세포를 동일한 밀도로 증식시킨 플레이트에 MDI(3-isobutyl-1-methylxanthine, dexamethasone, IBMX, dexamethasone)을 처리하여 분화된 지방세포에 시료와 인슐린(insulin)을 함께 처리함으로서 지방축적을 유도하면서 시료가 지방축적을 얼마나 억제하는지 비교하였다. 모든 처리구는 4∼8일간의 지방축적 유도 및 시료처리기간 이후 생성된 지방을 oil red-O 시약으로 지방을 염색하고 염색된 지방은 propanol을 이용하여 용출시킨 후 microplate reader로 520 nm에서 측정하여 축적된 지방량을 비교하였다.The anti-obesity activity of the Cornus officinalis extract of the present invention was confirmed. Specifically, the anti-obesity effect of the Cornus officinalis extract prepared in Example 1 was evaluated in the 3T3-L1 cell line using Oil red staining. Specifically, the Oil red-O assay treats MDI (3-isobutyl-1-methylxanthine, dexamethasone, IBMX, dexamethasone) on a plate grown with 3T3-L1 cells at the same density, and injects the differentiated adipocytes with a sample and insulin. By treating together, we compared how well the samples inhibited fat accumulation while inducing fat accumulation. In all treatment groups, fat accumulation was induced for 4 to 8 days and the fat produced after the sample processing period was stained with oil red-O reagent, and the stained fat was eluted using propanol and then measured and accumulated at 520 nm with a microplate reader. The amount of fat gained was compared.
그 결과, 본 발명의 산수유 추출물은 지방 축적을 억제하는 것을 확인하였으며, 산수유 과육 추출물에서, 미성숙과 추출물인 F1이 가장 우수한 항비만 효과를 나타내었다(도 3). 또한, 씨앗을 제거한 산수유(씨앗 포함) 추출물에서도, 산수유 미성숙과인 FS1이 항비만 효과가 우수한 것을 확인하였다(도 4). 또한, 산수유(씨앗 포함) 추출물이, 산수유 과육 추출물보다 지방 축적 억제효과가 우수한 것을 확인하였다(도 5).As a result, it was confirmed that the Cornus officinalis extract of the present invention inhibits fat accumulation, and in the Cornus officinalis pulp extract, F1, an immature fruit extract, showed the best anti-obesity effect (FIG. 3). In addition, it was confirmed that FS1, an immature Cornus officinalis fruit, had an excellent anti-obesity effect in the extract of Cornelian cherry (including seeds) with the seeds removed (Figure 4). In addition, it was confirmed that Cornus officinalis (including seeds) extract had a superior fat accumulation inhibitory effect than Cornus officinalis pulp extract (Figure 5).
<3-2> 산수유 추출물의 지방 축적 단백질 발현 억제 확인<3-2> Confirmation of inhibition of fat storage protein expression in Cornus officinalis extract
본 발명의 산수유 추출물이, 지방 축적과 관련된 단백질의 발현을 억제시키는지 확인하였다. 구체적으로, 3T3-L1 세포주에서 상기 실시예 1에서 제조된 산수유 추출물 중 F1, F3, FS1 및 FS3를 각각 50, 100 및 200 μg/ml로 처리한 후, 지방 축적과 관련된 단백질인 PPAR-γ, C/EBP-α 및 C/EBP-β의 발현량을 웨스턴 블랏으로 분석하였다.It was confirmed whether the Cornus officinalis extract of the present invention inhibits the expression of proteins related to fat accumulation. Specifically, after treating the 3T3-L1 cell line with 50, 100, and 200 μg/ml, respectively, of F1, F3, FS1, and FS3 from the Cornus officinalis extract prepared in Example 1, PPAR-γ, a protein related to fat accumulation, The expression levels of C/EBP-α and C/EBP-β were analyzed by Western blot.
그 결과, 도 6 내지 도 9에 나타낸 바와 같이, 대조군과 비교하여, 산수유 추출물을 처리한 군에서는 지방 축적과 관련된 단백질의 발현이 유의적으로 감소하였으며, 특히, 산수유 미성숙과 추출물인 F1 및 FS1가 지방 축적 관련 단백질 발현 억제능이 우수한 것을 확인하였다.As a result, as shown in Figures 6 to 9, compared to the control group, the expression of proteins related to fat accumulation was significantly reduced in the group treated with Cornus officinalis extract. In particular, F1 and FS1, extracts of immature Cornus officinalis fruit, were It was confirmed that it had excellent ability to suppress the expression of proteins related to fat accumulation.
<실시예 4> 산수유 추출물의 추출 용매에 따른 세포 독성 확인<Example 4> Confirmation of cytotoxicity according to extraction solvent of Cornus officinalis extract
본 발명의 산수유 추출물의 용매에 따른 세포 독성을 확인하였다. 구체적으로 상기 실시예 2와 동일한 방법으로 MTT assay로 분석하였으며, 산수유 용매에 따라, 산수유(씨앗 포함) 물 또는 에탄올 추출물(F W 또는 FS 70E)과 산수유 과육 물 또는 에탄올 추출물(F W 또는 F 70E)의 세포 독성을 확인하였다.The cytotoxicity of the Cornus officinalis extract according to the solvent of the present invention was confirmed. Specifically, it was analyzed by MTT assay in the same manner as in Example 2, and depending on the Cornus officinalis solvent, the concentration of Cornus officinalis (including seeds) water or ethanol extract (F W or FS 70E) and Cornus officinalis pulp water or ethanol extract (F W or F 70E) Cytotoxicity was confirmed.
그 결과, 도 10에 나타낸 바와 같이, 본 발명의 산수유 추출물들을 100 μg/ml 미만의 농도에서는 세포 독성을 나타내지 않는 것을 확인하였다.As a result, as shown in Figure 10, it was confirmed that the Cornus officinalis extract of the present invention did not exhibit cytotoxicity at a concentration of less than 100 μg/ml.
<실시예 5> 산수유 추출물의 추출 용매에 따른 항비만 효과 확인<Example 5> Confirmation of anti-obesity effect according to extraction solvent of Cornus officinalis extract
본 발명의 산수유 추출물의 용매에 따른 항비만 효과를 확인하였다. 구체적으로, 상기 실시예 1에서 제조된 산수유 70% 주정 추출물 및 물 추출물을 이용하여, 지방 축적 억제 효과를 확인하였다.The anti-obesity effect of the Cornus officinalis extract according to the solvent of the present invention was confirmed. Specifically, the effect of inhibiting fat accumulation was confirmed using the 70% alcohol extract and water extract of Cornus officinalis prepared in Example 1.
그 결과 도 11에 나타낸 바와 같이, 모든 산수유 추출물에서, 지방축적이 억제되는 것을 확인하였으며, 특히, 씨를 포함한 산수유 추출물(FS1 및 FS3)에서, 지방 축적억제 효과가 우수하였다. 또한, 70% 주정 추출물이(FS1 70E 및 FS3 70E), 물 추출물(F1 W 및 F3 W)보다 지방축적 억제 효과가 유의적으로 우수하였으며, 모든 추출물 중에서, 산수유 미숙과 추출물(F1 W, F1 70E)이 항지방 억제 효과가 우수한 것을 확인하였다.As a result, as shown in Figure 11, it was confirmed that fat accumulation was suppressed in all Cornus officinalis extracts, and in particular, Cornus officinalis extracts containing seeds (FS1 and FS3) had an excellent effect of suppressing fat accumulation. In addition, the 70% alcohol extract (FS1 70E and FS3 70E) had a significantly better effect on inhibiting fat accumulation than the water extract (F1 W and F3 W), and among all extracts, the unripe Cornus officinalis fruit extract (F1 W, F1 70E) ) was confirmed to have excellent anti-fat suppressing effect.
<실시예 6> 산수유 추출물의 유효물질 확인<Example 6> Confirmation of active substances in Cornus officinalis extract
본 발명의 산수유 추출물의 유효물질을 분석하였다. 구체적으로, 상기 실시예 1에서 제조된 산수유 추출물을 HPLC 분석으로, 산수유의 대표적인 유효물질인, 갈릭산(gallic acid), 모로니사이드(Morroniside), 로가닌(Loganin), 베르베날린(Verbenalin), 스와로사이드(Sweroside) 및 콘누사이드(Cornuside)를 확인하였다.The active substances of the Cornus officinalis extract of the present invention were analyzed. Specifically, through HPLC analysis of the Cornus officinalis extract prepared in Example 1, the representative active substances of Cornus officinalis, including gallic acid, Morroniside, Loganin, and Verbenalin, were analyzed. ), Sweroside, and Cornuside were identified.
그 결과, 도 12 내지 도 17에 나타낸 바와 같이, 산수유의 대표적인 기능성분 6종을 확인하였다. 구체적으로, 산수유(씨앗 포함) 추출물과, 산수유 과육 추출물 모두에서 갈릭산(gallic acid), 로가닌(Loganin) 및 콘누사이드(Cornuside)의 함량은 유의적인 차이가 없었으나, 산수유의 수확 시기에 따라서, 미숙과(9월 수확)에서, 성숙과(10월 내지 12월 수확)보다 유의적으로 함량이 증가된 것을 확인하였다.As a result, as shown in Figures 12 to 17, six representative functional ingredients of Cornus officinalis were identified. Specifically, there was no significant difference in the contents of gallic acid, Loganin, and Cornuside in both Cornus officinalis (including seeds) extract and Cornus officinalis pulp extract, but at the harvest time of Cornus officinalis Therefore, it was confirmed that the content of immature fruits (harvested in September) was significantly increased compared to mature fruits (harvested from October to December).
또한, 산수유 과육 추출물에서는 모로니사이드(Morroniside)가 산수유(씨앗 포함) 추출물보다 유의적으로 함량이 증가된 것을 확인하였으며, 산수유(씨앗 포함) 추출물에서는, 베르베나림(Verbenalim) 및 스와로사이드(Sweroside)의 함량이 산수유 과육 추출물과 비교하여, 유의적으로 함량이 증가된 것을 확인하였다.In addition, it was confirmed that the content of Morroniside was significantly increased in the Cornus officinalis pulp extract compared to the extract of Cornus officinalis (including seeds), and in the extract of Cornus officinalis (including seeds), Verbenalim and Swaroside ( Sweroside) content was confirmed to be significantly increased compared to Cornus officinalis pulp extract.
따라서, 본 발명은, 산수유 미성숙과 추출물이, 지방축적 억제 효과가 우수한 것을 확인하였으며, 지방 축적과 관련된 단백질의 발현을 억제시키는 것을 확인하였다. 또한, 산수유 미성숙과 추출물 중 씨앗을 포함한 추출물이, 과육 추출물보다 지방축적 및 지방 축적 단백질의 발현을 억제시키는 효과가 우수한 것을 확인하였으며, 산수유 미성숙과 추출물에서, 갈릭산(gallic acid), 모로니사이드(Morroniside), 로가닌(Loganin), 베르베날린(Verbenalin), 스와로사이드(Sweroside) 및 콘누사이드(Cornuside)의 함량이 증가된 것을 확인하였다.Therefore, the present invention confirmed that the extract of immature Cornus officinalis had an excellent effect in suppressing fat accumulation and suppressed the expression of proteins related to fat accumulation. In addition, it was confirmed that among the extracts of immature Cornus officinalis fruit, extracts containing seeds were more effective than pulp extracts in suppressing fat accumulation and the expression of fat accumulation proteins. In the extracts of immature Cornus officinalis fruit, gallic acid and moroniside were found. It was confirmed that the contents of Morroniside, Loganin, Verbenalin, Sweroside, and Cornuside were increased.
Claims (19)
상기 산수유는, 미숙과(immature fruit)인 것인, 식품조성물.According to clause 1,
The Cornus officinalis is a food composition, which is an immature fruit.
상기 산수유는 씨앗(seed)를 더 포함하는 것인, 식품조성물.According to clause 1,
A food composition in which the Cornus officinalis further includes seeds.
상기 추출물은 물, C1 내지 C4의 저급 알코올, 저급 알코올 수용액, 핵산, 클로로포름 및 아세톤으로 이루어진 군에서 선택된 용매로 추출되는 것인, 식품조성물.According to clause 1,
The food composition, wherein the extract is extracted with a solvent selected from the group consisting of water, C1 to C4 lower alcohol, lower alcohol aqueous solution, nucleic acid, chloroform, and acetone.
상기 용매는 물 또는 저급 알코올 수용액인 것인, 식품조성물.According to clause 4,
A food composition wherein the solvent is water or a lower alcohol aqueous solution.
상기 추출물은 산수유 및 용매가 1 : 20의 중량비로 혼합되어 추출되는 것인, 식품조성물.According to clause 1,
The extract is a food composition that is extracted by mixing Cornus officinalis and a solvent at a weight ratio of 1:20.
상기 추출물은 지방 축적을 억제하는 것인, 식품조성물.According to clause 1,
The extract is a food composition that inhibits fat accumulation.
상기 추출물은, 지방 합성 인자의 발현을 억제시키는 것인, 식품조성물.According to clause 1,
The extract is a food composition that inhibits the expression of fat synthesis factors.
상기 지방 합성 인자는, PPAR-γ, C/EBP-α 또는 C/EBP-β인 것인, 식품조성물.According to clause 8,
The food composition wherein the fat synthesis factor is PPAR-γ, C/EBP-α or C/EBP-β.
상기 추출물은, 갈릭산(gallic acid), 모로니사이드(Morroniside), 로가닌(Loganin), 베르베날린(Verbenalin), 스와로사이드(Sweroside) 및 콘누사이드(Cornuside)로 이루어진 군에서 선택된 기능성분의 함량이 증가된 것인, 식품조성물.According to clause 1,
The extract has a function selected from the group consisting of gallic acid, Morroniside, Loganin, Verbenalin, Sweroside and Cornuside. A food composition with an increased content of ingredients.
상기 세척된 산수유를 용매에 침지하는 단계;를 포함하는, 산수유 추출물의 제조 방법.Washing Cornus officinalis; and
A method for producing Cornus officinalis extract, comprising: immersing the washed Cornus officinalis in a solvent.
상기 추출물은 갈릭산(gallic acid), 모로니사이드(Morroniside), 로가닌(Loganin), 베르베날린(Verbenalin), 스와로사이드(Sweroside) 및 콘누사이드(Cornuside)로 이루어진 군에서 선택된 기능성분의 함량이 증가된 것인, 방법.According to clause 12,
The extract contains functional ingredients selected from the group consisting of gallic acid, Morroniside, Loganin, Verbenalin, Sweroside, and Cornuside. A method in which the content of is increased.
상기 산수유는, 미숙과(immature fruit)인 것인, 방법.According to clause 12,
The method wherein the Cornus officinalis is an immature fruit.
상기 산수유는, 씨앗(seed)를 더 포함하는 것인, 방법.According to clause 12,
The method wherein the Cornus officinalis further includes seeds.
상기 세척된 산수유를 용매에 침지하는 단계;를 포함하는, 산수유 추출물에서, 갈릭산(gallic acid), 모로니사이드(Morroniside), 로가닌(Loganin), 베르베날린(Verbenalin), 스와로사이드(Sweroside) 및 콘누사이드(Cornuside)로 이루어진 군에서 선택된 기능성분을 증가시키는 방법.Washing Cornus officinalis; and
In the Cornus officinalis extract, including the step of immersing the washed Cornus officinalis in a solvent, gallic acid, Morroniside, Loganin, Verbenalin, and Swaroside A method of increasing a functional ingredient selected from the group consisting of Sweroside and Cornuside.
상기 산수유는, 미숙과(immature fruit)인 것인, 방법.According to clause 16,
The method wherein the Cornus officinalis is an immature fruit.
상기 산수유는, 씨앗(seed)를 더 포함하는 것인, 방법.According to clause 16,
The method wherein the Cornus officinalis further includes seeds.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020220062967A KR20230163185A (en) | 2022-05-23 | 2022-05-23 | Composition for the prevention or treatment of obesity comprising an immature fruit extract of Cornus officinalis as an active ingredient |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020220062967A KR20230163185A (en) | 2022-05-23 | 2022-05-23 | Composition for the prevention or treatment of obesity comprising an immature fruit extract of Cornus officinalis as an active ingredient |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230163185A true KR20230163185A (en) | 2023-11-30 |
Family
ID=88968433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020220062967A KR20230163185A (en) | 2022-05-23 | 2022-05-23 | Composition for the prevention or treatment of obesity comprising an immature fruit extract of Cornus officinalis as an active ingredient |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20230163185A (en) |
-
2022
- 2022-05-23 KR KR1020220062967A patent/KR20230163185A/en not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230082624A1 (en) | Composition, containing quisqualis indica extract, for preventing or treating prostatic hyperplasia | |
| KR101427784B1 (en) | An anti-diabetes composition comprising Ginseng Radix and mulberry tree extract as effective ingredients | |
| KR102414431B1 (en) | A composition for improving, preventing and treating of diabetes mellitus | |
| KR102236685B1 (en) | Composition for preventing or treating lipid metabolism diseases comprising extract of salvia miltiorrhiza or paeonia lactiflora | |
| KR102151011B1 (en) | Composition for preventing, improving or treating liver disease comprising fermented liquor of aged sprout ginseng extract as effective component | |
| KR102487651B1 (en) | A composition for preventing, improving or treating sarcopenia comprising extracts of wheat sprout | |
| KR20230163185A (en) | Composition for the prevention or treatment of obesity comprising an immature fruit extract of Cornus officinalis as an active ingredient | |
| KR102411428B1 (en) | Composition for improvementing, preventing or treating obesity and metabolic diseases comprising fractions or extract of molokhia leave | |
| KR101808808B1 (en) | Compositions for preventing and treating diabetes or diabetic complications comprising extracts of Acer tegmentosum Maximowoca and Magnolia officinalis Rehd. et Wils. | |
| KR101018404B1 (en) | Compositions for reducing cholesterol comprising extracts of Vaccinium oldhami Miquel leaf as an active ingredient | |
| KR20160094313A (en) | Composition for anti-obesity comprising Chaenomelis Fructus extract or its fraction as effective component | |
| KR20210074865A (en) | Pharmaceutical composition for preventing or treating diabetes, including extract of fermented tea leaves | |
| KR20100108869A (en) | Composition containing extract of herbal mixture for prevention or treatment of diabetes | |
| KR20130082249A (en) | Composition for preventing or improving the metabolic syndrome containing parthenocissus tricuspidata extract | |
| KR102496864B1 (en) | Anti-obesity composition containing extract of Paliurus ramosissimus as an active ingredient | |
| KR102624965B1 (en) | A composition for enhancing exercise performance and fatigue recovery, containing fermented ripen Noni, Coconut sugar and Muscovado sugar as active ingredients | |
| KR101712889B1 (en) | Pharmaceutical composition comprising Zingiber mioga extracts or its fractions for prevention and treatment of neurodegenerative disorders as an active ingredient | |
| KR101839908B1 (en) | Food composition improving of diabetes and Composition containing extract of herbal mixture for prevention or treatment of diabetes | |
| KR20230161341A (en) | Composition for prevention, improvement or treatment of arthritis and joint pain comprising Lysimachia mauritiana extract as effective component | |
| KR100526626B1 (en) | Anti-diabetic drug containing alcohol extract of Panax ginseng leaves | |
| KR20220117584A (en) | A composition for preventing or improving diabetes containing a radish extract as an active ingredient and a method for producing the same | |
| KR101904819B1 (en) | Composition comprising Fermented Momordica charantia L. and Allium sativum L. using Amyloliquefaciens Bacillus Jis-1 for lowering blood glucose or preventing and treating diabetes mellitus | |
| KR20230161339A (en) | Composition for prevention, improvement or treatment of arthritis and joint pain comprising Ribes fasciculatum var. chinense extract as effective component | |
| KR100567263B1 (en) | Composition for inhibiting liver cancer containing an extract of the root bark of ulmus davidiana var | |
| KR20230161338A (en) | Composition for prevention, improvement or treatment of arthritis and joint pain comprising Spiraea prunifolia var. simpliciflora extract as effective component |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E902 | Notification of reason for refusal |